Latest Medical Technology from Bio-Medicine.Org

AMD LASERS Announces New Partnership with Dr. Larry Rosenthal and Aesthetic Advantage

Mon, 23 Nov 2009 06:43:12 MST

INDIANAPOLIS,Nov.23/PRNewswire/--AMDLASERSannouncedthisweekthatitcontinueswithanongoingcommitmenttodentaleducationbypartneringwithprestigiousindustry-leaderDr.LarryRosenthalandAestheticAdvantage.Picasso,byAMDLASERS,willbetheexclusivesofttissuediodelaserusedduringallinternationaleducationalactivities,whicharetargetedtothetop2%ofdentists. (Photo: http://www.newscom.com/cgi-bin/prnh/2...

Cord Blood America CEO Matthew Schissler Interviewed on Company's Progress

Mon, 23 Nov 2009 06:42:56 MST

LASVEGAS,Nov.23/PRNewswire-FirstCall/--CordBloodAmerica,Inc.(OTCBulletinBoard:CBAI),theumbilicalcordbloodstemcellpreservationcompany( http://www.cordblood-america.com )focusedonbringingthelifesavingpotentialofstemcells,abiologicalinsurancepolicy,tofamiliesnationwideandinternationally,announcedtodaythatanupdatedprogressinterviewwithCEOandco-founderMatthewSchisslerisnowavailable. The...

Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger

Mon, 23 Nov 2009 06:42:24 MST

SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-FirstCall/--Anesiva,Inc.(Nasdaq: ANSV )todayannouncedthatDr.TedW.LoveandDr.DavidC.U'PrichardhaveagreedtojointheAnesivaboardofdirectorsfollowingcompletionoftheproposedmergerbetweenAnesivaandArcionTherapeutics.CompletionofthemergerissubjecttoashareholdervotescheduledtotakeplaceatthepreviouslyannouncedAnesiva2009AnnualMeetingofStockholders,tobeheld...

Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C

Mon, 23 Nov 2009 06:42:18 MST

PRINCETON,N.J.,Nov.23/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS )announcedtodaythattheenrollmentofCohort2,ledbyitspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willcontinuefortheremaining300genotype1and4patientsintheongoingphase2btrialofRG7128,afirst-in-classnucleosideanalogpolymeraseinhibitorforthetreatmentofchronichepatitisCvirus(HCV)infection.Thedecisionwasreachedafterascheduled...

Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain

Mon, 23 Nov 2009 06:42:04 MST

NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--RaptorPharmaceuticalCorp.("Raptor"orthe"Company")(Nasdaq: RPTP )todayannouncedthepresentationofclinicaltrialdataonNGX426,theCompany'sorallyadministered,non-opioid,AMPA/kainatereceptorantagonist,atthe12thInternationalConferenceontheMechanismsandTreatmentofNeuropathicPain,heldonNovember20-21inSanFrancisco.TheresultsofthestudyledbyMarkWallace,M.D....

Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis

Mon, 23 Nov 2009 06:41:50 MST

NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--RaptorPharmaceuticalCorp.("Raptor"orthe"Company")(Nasdaq: RPTP ),todayannouncedresultsfromaPhase2bclinicaltrialofitsproprietarydelayed-releasecysteaminebitartrate("DRCysteamine")inpatientswithnephropathiccystinosis("cystinosis").Thetrial,conductedattheUniversityofCalifornia,SanDiego("UCSD")GeneralClinicalResearchCenter,evaluatedsafety,tolerabil...

Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference

Mon, 23 Nov 2009 06:41:36 MST

SCHAUMBURG,Ill.,Nov.23/PRNewswire/--SagentPharmaceuticals,Inc.,aprivately-heldspecialtypharmaceuticalcompanywithafocusoninjectableproducts,todayannouncedthatJefferyM.Yordon,chiefexecutiveofficer,founderandchairmanoftheboardofSagentPharmaceuticals,willpresentatthe21stAnnualPiperJaffrayHealthCareConferenceonTuesday,December1,2009at9:30ameasterntimeattheNewYorkPalaceHotelinNewYorkCity,NY....

Oceanside Pharmaceuticals Announces Launch of Librax(R) AG

Mon, 23 Nov 2009 06:41:20 MST

ALISOVIEJO,Calif.,Nov.23/PRNewswire-FirstCall/--Oceanside Pharmaceuticals ,partofValeant Pharmaceuticals International(NYSE: VRX ),todayannouncedthatithasnowlaunchedchlordiazepoxidehydrochlorideandclidiniumbromide,anauthorizedgeneric(AG)versionofLibrax®.OceansidehasreceiveditsfirstordersandexpectstobeasignificantplayerintheLibrax®genericmarket. "Valeant'sOceansideunithasb...

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis

Mon, 23 Nov 2009 06:40:24 MST

MALVERN,Pa.andFRAZER,Pa.,Nov.23/PRNewswire-FirstCall/--CeptionTherapeutics,Inc.,aprivatelyheldbiopharmaceuticalcompany,andCephalon,Inc.(Nasdaq: CEPH )todayannouncedresultsfromaPhaseIIb/IIIclinicaltrialforCINQUIL(TM)(reslizumab)asatreatmentforpediatriceosinophilicesophagitis(EoE).Thestudywasdesignedtoevaluateimprovementintheco-primaryendpointsofchangesinesophagealeosinophillevelsandclinic...

Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share

Mon, 23 Nov 2009 06:24:14 MST

EMERYVILLE,Calif.,Nov.23/PRNewswire-FirstCall/--NeurobiologicalTechnologies,Inc.(Nasdaq: NTII )("NTI")announcedtodaythatitsboardofdirectorshasdeclaredanextraordinarydividendof$0.18pershareofcommonstock,whichwillbepaidonDecember9,2009tostockholdersofrecordasofNovember30,2009.TheDecember9,2009extraordinarydividendfollowsstockholderapprovalofthedissolutionofNTIpursuanttoaplanofcompleteliqui...

Neonatal Scenarios Developed in Partnership with the American Academy of Pediatrics (AAP), Utilize the NRP Curriculum to Advance Newborn Care

Mon, 23 Nov 2009 04:16:15 MST

WAPPINGERSFALLS,N.Y.,Nov.23 /PRNewswire/-- LaerdalMedical,inalliancewiththeAmericanAcademyofPediatrics(AAP),hasdevelopedasecondvolumeofpre-programmedscenariosforusewithLaerdal'sSimNewB(TM)neonatalpatientsimulator.SimNewBisdesignedtointegratesimulationintotheAAP'sNeonatalResuscitationProgramandtofacilitatetrainingfortreatmentofothercriticalmedicalconditionsintheneonatalperiod. (Lo...

ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities

Mon, 23 Nov 2009 02:01:16 MST

IRVINE,Calif.,Nov.23/PRNewswire/--AdvancedSterilizationProducts(ASP),aleadingglobalinfectionpreventionsolutionprovider,announcedtodaytheacquisitionbyitsFrenchaffiliate,ApsisS.A.S.,ofGlosterEurope,aprivatelyhelddeveloperofinnovativedisinfectionprocessesandtechnologiestopreventhealthcare-acquiredinfections.Termsoftheacquisitionwerenotdisclosed. GlosterEuropedesignsandmarketsaninnovat...

ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries

Sat, 21 Nov 2009 01:11:18 MST

WASHINGTON, Nov. 21 /- An urgent need for new medicines to treat neglected infectious diseases in the developing world has prompted a growing number of collaborations among academic researchers, non-profit product development partnerships (PDPs), and pharmaceutical and biotechnology companies. As noted today in a symposium at the 58th annual meeting of the American Society...

Escalon(R) Reports First Quarter Fiscal 2010 Results

Fri, 20 Nov 2009 07:34:06 MST

WAYNE, Pa., Nov. 20 /- Escalon Medical Corp. (Nasdaq Market: ESMC) announced the results for its fiscal first quarter ended September 30, 2009. For the first quarter of fiscal 2010, product revenue decreased approximately $234,000, or 2.7%, to $8,435,000 during the three-month period ended September 30, 2009 as compared to the same period last fiscal yea...

U.S. Court of Appeals Upholds AstraZeneca AWP Settlement

Fri, 20 Nov 2009 07:33:39 MST

BOSTON, Nov. 20 /- The United States Court of Appeals for the First Circuit upheld an earlier District Court ruling yesterday, approving a settlement in the long-running Average Wholesale Price (AWP) pharmaceutical litigation against AstraZeneca Pharmaceuticals ( AZN). (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) The ruling affirms a s...

Unilens Vision Reports Record First Quarter Earnings and Royalty Income

Fri, 20 Nov 2009 04:12:45 MST

LARGO, Fla., Nov. 20 /- Unilens Vision Inc. (OTC Bulletin Board: UVICF; TSX Venture Exchange: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the first quarter ended September 30, 2009 (FY2010). Net sales excluding royalty income, were $1,683,673 in the FY2010 first qu...

Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal

Fri, 20 Nov 2009 04:12:29 MST

CARY, N.C., Nov. 20 /- Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today reported that it had received a Warning Letter from the Food and Drug Administration ("FDA") alleging that its Deconsal CT che...

National System Aims To Minimize Diversion of Cold and Allergy Medicine in Methamphetamine Production

Fri, 20 Nov 2009 04:12:17 MST

LOUISVILLE, Ky., Nov. 20 /- The National Association of Drug Diversion Investigators (NADDI) today announced a new initiative in the war on methamphetamine. The National Precursor Log Exchange (NPLEx) is a multi-state electronic tracking program that enforces purchase limitations on over-the-counter (OTC) medicines containing pseudoephedrine in real-time at the point...

Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results

Fri, 20 Nov 2009 01:07:51 MST

GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- Landauer, Inc. ( LDR) , will release financial results for the fiscal fourth quarter and full year of 2009 pre-market on Tuesday, December 1, 2009. The company will host a conference call for investors on Tuesday, December 1, 2009, at 2:00 p.m. Eastern Time. Investors may access the live call by dialing 877-941-9205 (within...

Medco Reforming Healthcare with 'Smarter Medicine'; Wired, Transformational Pharmacy Model Advances Clinical Quality and Lowers Cost

Fri, 20 Nov 2009 01:07:34 MST

NEW YORK, Nov. 20 /- Medco Health Solutions, Inc (NYSE: MHS ) is today contributing to a transformation in American healthcare through an advanced, wired pharmacy paradigm that is already delivering higher quality clinical care and fundamentally bending the cost curve downward -- making medicine smarter for the benefit of patients and payors alike. The...